Interstitial Lung Disease Clinical Trials in Chicago, Illinois

4 studies are recruiting for interstitial lung disease in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Pulmonary Fibrosis Foundation Community Registry

    Pulmonary fibrosis (PF) results from a diverse group of health conditions and affects the lives of patients (including those who are post lung transplant), caregivers and family members. The Pulmonary Fibrosis Foundation Community Registry will offer an online portal where participants can self-enr…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Pulmonary Fibrosis Foundation, Chicago, Illinois
    Run by
    Pulmonary Fibrosis Foundation

    See if you can join NCT05382572 on ClinicalTrials.gov

  2. DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

    This is a prospective, real world, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and interstitial lung disease (ILD).

    Stage
    Not phased
    Ages
    18 and older
    Site
    Northwestern University, Chicago, Illinois
    Locations
    71 in total
    Run by
    United Therapeutics

    See if you can join NCT06388421 on ClinicalTrials.gov

  3. Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

    Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Northwestern Memorial Hospital, Clinical Research Unit, Chicago, Illinois
    Locations
    165 in total
    Run by
    United Therapeutics

    See if you can join NCT05943535 on ClinicalTrials.gov

  4. Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

    This is a 2-Part study with Part A, a double-blind, randomized, placebo-controlled, PoC study to evaluate the efficacy, safety, and tolerability of efzofitimod in patients with SSc-ILD. The primary objective of the study is to evaluate the PoC for efficacy in a population with SSc-ILD. While improv…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    aTyr Investigative Site, Chicago, Illinois
    Locations
    15 in total
    Run by
    aTyr Pharma, Inc.

    See if you can join NCT05892614 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.